摘要
目的:本研究以原发性肺癌患者为研究对象,在蛋白质水平探讨CD10、CD13和CTAg作为特异性肿瘤标记物对原发性肺癌的诊断、鉴别诊断、判断病情进展及预后的临床价值。
方法:收集原发性肺癌病例73例,其中包括鳞癌27例,腺癌30例,小细胞肺癌16例,采用免疫组织化学方法分别检测CD10、CD13和CTAg在上述病例手术切除标本中的表达,并与癌旁组织、26例肺良性肿瘤、20例正常肺组织进行比较。
结果:1、CD10的表达:①在73例肺癌标本中CD10表达阳性率为32.88%(24/73),肺良性肿瘤阳性率88.46%(23/26),正常肺组织阳性率95.00%(19/20),CD10在肺癌中的表达明显低于肺良性肿瘤及正常肺组织(P＜0.001)。②73例肺癌间质细胞CD10阳性率63.01%(46/73),癌旁组织阳性率94.52%(69/73),CD10在肺癌间质细胞中的表达明显低于在正常肺组织、癌旁组织中的表达(P＜0.001)。③腺癌、鳞癌、小细胞癌中CD10表达阳性率为分别为50%(15/30)、22.22%(6/27)、18.75%(3/16),肺癌临床Ⅰ、Ⅱ、Ⅲ～Ⅳ中CD10表达阳性率分别为73.33%(11/15)、22.22%(4/18)、22.50%(9/40),肺癌高、中、低分化中CD10表达阳性率分别为71.43%(5/7)、38.71%(12/31)、20.00%(7/35),有无淋巴结转移中CD10表达阳性率分别为21.95%(9/41)、46.87%(15/32)。CD10在肺癌中的表达与肺癌病理分型、临床分期、组织分化程度及淋巴结转移有相关性(P＜0.05)。
2、CD13的表达:①在73例肺癌标本中CD13表达阳性率为41.10%(30/73),肺良性肿瘤阳性率15.38%(4/26),正常肺组织组阳性率5%(1/20),CD13在肺癌中表达明显高于肺良性肿瘤及正常肺组织(P＜0.05)。②73例肺癌间质细胞CD13阳性率36.98%(27/73),癌旁组织阳性率17.81%(13/73),CD13在肺癌间质细胞中的表达明显高于癌旁肺组织及正常肺组织(P＜0.05)。③腺癌、鳞癌、小细胞癌中CD13表达阳性率为分别为70%(21/30)、29.63%(8/27)、6.25%(1/16)。肺癌临床Ⅰ、Ⅱ、Ⅲ-Ⅳ中CD13表达阳性率分别为6.67%(1/15)、52.50%(21/40)、44.44%(8/18)。肺癌高、中、低分化中CD13表达阳性率分别为14.29%(1/7)、60.00%(21/35)、25.81%(8/31)。有无淋巴结转移中CD13表达阳性率分别为60.98%(25/41)、15.63%(5/32)。CD10在肺癌中的表达与肺癌病理分型、临床分期、组织分化程度及淋巴结转移有相关性(P＜0.05)。
3、CTAg的表达:①73例肺癌标本中,NY-ESO-1阳性表达33例,阳性率45.21%(33/73),MAGE-A1阳性表达41例,阳性率56.16%(41/73),癌旁组织、肺良性肿瘤、正常肺组织中均无NY-ESO-1和MAGE-1表达。②腺癌、鳞癌、小细胞癌中NY-ESO-1表达阳性率为分别为70%(21/30)、33.33%(9/27)、18.75%(3/16),MAGE-A1表达阳性率为分别为83.33%(25/30)、25.93%(7/27)、56.25%(9/16)。肺癌临床Ⅰ、Ⅱ、Ⅲ-Ⅳ中NY-ESO-1表达阳性率分别为26.67%(4/15)、27.78%(5/18)、60.00%(24/40),MAGE-A1表达阳性率为分别为60.00%(9/15)、61.11%(11/18)、52.50%(21/40)。肺癌高、中、低分化中NY-ESO-1表达阳性率分别为28.57%、29.03%(9/31)、62.86%(22/35),MAGE-A1表达阳性率为分别为42.86%(3/7)、35.48%(11/31)、77.14%(27/35)。有无淋巴结转移中NY-ESO-1表达阳性率分别为56.98%(23/41)、31.25%(10/32),MAGE-A1表达阳性率为分别为53.66%(22/41)、59.38%(19/32)。NY-ESO-1在肺癌中的表达与肺癌病理分型、临床分期、组织分化程度及淋巴结转移有相关性(P＜0.05)。MAGE-A1在肺癌中的表达与肺癌病理分型、组织分化程度有相关性(P＜0.05),与临床分期、淋巴结转移无明显相关性(P＞0.05)。
结论:1、CD10在肺癌细胞、肿瘤间质细胞中的表达显著降低,CD10可以作为有价值的肿瘤标记物用于肺癌的诊断和鉴别诊断。CD10的表达与肺癌患者的年龄、病理分型、组织分化程度、临床分期、淋巴结转移有相关性,对肺癌的预后判断有指导意义。2、CD13在肺癌细胞、肿瘤间质细胞呈高表达,CD13可以作为一种独立肿瘤标记物应用于肺癌的诊断和鉴别诊断。CD13的表达与肺癌患者的病理分型、组织分化程度、临床分期、淋巴结转移均有明显相关性,对肺癌的预后判断有指导意义。3、NY-ESO-1和MAGE-A1在癌旁组织、肺良性肿瘤、正常肺组织中均无表达,只在肺癌中特异性表达,是特异性肺癌标记物。NY-ESO-1的表达与肺癌患者的病理分型、组织分化程度、临床分期、淋巴结转移有明显相关性。4、四种抗原都具有较强特异性,但单独表达的敏感性相对较差,联合检测,起到互补作用,可以从不同的侧面,较全面地反映肿瘤细胞的生物学特性,对肺癌的诊断、鉴别诊断、治疗效果的评价,预后的判断有着重要的指导意义。
Objective:To investigate the relationship that expression of CD10,CD13 and CTAg in protein level as a specific tumor marker to diagnosis,differential diagnosis,disease prediction and prognosis of primary pulmonary carcinoma.
Methods:In 73 cases of primary pulmonary carcinoma,including 27 cases of squamous cell carcinoma,30 cases of adenocarcinoma,16 cases of small cell lung cancer, the CD10,CD13 and CTAg expression were detected by means of immunohistochemistry and were compared with adjacent lung tissues,26 pulmonary benign tumors,20 cases of normal lung tissue.
Results:1、The expression of CD10:①24 of 73 cases of pulmonary carcinoma were CD10 positive(32.88%),and 23 of 26 eases of pulmonary benign tumors were CD10 positive(88.46%).19 of 20 eases of common lungs were CD10 positive(95%).The positive expression of CD10 in pulmonary carcinoma was significantly lower than in pulmonary benign tumors and common lung(P＜0.05).②46 of 73 cases of pulmonary carcinoma stromal cells were CD10 positive(63.01%),69 of 73 cases of lung cancer adjacent tissues were CD10 positive(94.52%),CD10 positive rates in lung cancer stromal cells was significantly lower than in normal lung tissue,cancer adjacent tissues(P＜0.001).③The positive expression of CD10 in lung adenocarcinoma,squamous cell carcinoma,small cell carcinoma were50%(15/30)、22.22%(6/27)、18.75%(3/16) respectively。The positive expression of CD10 in clinical stageⅠ、Ⅱ、Ⅲ～Ⅳwere 73.33%(11/15)、22.22% (4/18)、22.50%(9/40) respectively。The positive expression of CD10 in well, moderately and poorly differentiated pulmonary carcinoma were 71.43%(5/7)、38.71% (12/31)、20.00%(7/35) respectively.It was also shown the positive expression of CD10 in cases with lymph node metastasis(21.95%) was markedly lower than that in those without lymph node metastasis(46.87%).The expression of CD10 was related to pathological classification of lung cancer,clinical stage,pathological differentiation and lymph node metastasis(P＜0.05).
2、The expression of CD13:①30 of 73 cases of pulmonary carcinoma were CD13 positive(41.10%),and 4 of 26 eases of pulmonary benign tumors were CD13 positive(15.38%).1 of 20 eases of common lungs were CD13 positive(5%).The positive incidence of CD13 in pulmonary carcinoma was significantly lower that in pulmonary benign tumors and 20 cases of common lung(P＜0.05).②27 of 73 cases of lung cancer stromal cells were CD13 positive(36.98%),13 of 73 cases of lung cancer adjacent tissues were CD10/NEP positive(17.81%),CD13 positive in lung cancer stromal cells was significantly lower than in normal lung tissue,cancer adjacent tissues(P＜0.05).③The positive expression of CD 13 in lung adenocarcinoma,squamous cell carcinoma,small cell carcinoma were 70%(21/30)、29.63%(8/27)、6.25%(1/16 ) respectively。The positive expression of CD13 in clinical stageⅠ、Ⅱ、Ⅲ～Ⅳwere 6.67%(1/15)、52.50%(21/40)、44.44%(8/18) respectively.The positive expression of CD13 in well、moderately and poorly differentiated pulmonary carcinoma were 14.29%(1/7)、60.00%(21/35)、25.81% (8/31) respectively.It was also shown the positive expression of CD13 in cases with lymph node metastasis(60.98%) was markedly higher than that in those without lymph node metastasis(15.63%)。The expression of CD13 was related to pathological classification of lung cancer,clinical stage,pathological differentiation and lymph node metastasis(P＜0.05).
3、The expression of CTAg:①33 of 73 cases of pulmonary carcinoma were NY-ESO-1 positive(45.21%),41 of 73 cases of pulmonary carcinoma were MAGE-A1 positive(56.16%),Adjacent tissues,pulmonary benign tumors,normal lung tissues had no NY-ESO-1 and MAGE-1 expression.②The positive expression of NY-ESO-1 in lung adenocarcinoma,squamous cell carcinoma,small cell carcinoma were 70%(21/30)、33.33%(9/27)、18.75%(3/16) respectively.The positive rates of MAGE-A1 were83.33 %(25/30)、25.93%(7/27)、56.25%(9/16).The positive expression of NY-ESO-1 in clinical stageⅠ、Ⅱ、Ⅲ～Ⅳwere 26.67%(4/15)、27.78%(5/18)、60.00%(24/40).The positive rates of MAGE-A1 were60.00%(9/15)、61.11%(11/18)、52.50%(21/40) respectively.The positive expression of NY-ESO-1 in well、moderately and poorly differentiated pulmonary carcinoma were 28.57%、29.03%(9/31)、62.86%(22/35) respectively.The positive rates of MAGE-A1 were42.86%(3/7)、35.48%(11/31)、77.14%(27/35).It was also shown the positive expression of NY-ESO-1 in cases with lymph node metastasis(56.98%) was markedly higher than that in those without lymph node metastasis(31.25%).The expression of NY-ESO-1 was related to pathological classification of lung cancer,clinical stage,pathological differentiation and lymph node metastasis(P＜0.05).The expression of MAGE-A1 was also related to Pathological classification of lung cancer and pathological differentiation(P＜0.05),however, expression rate of MAGE-1 has no relationship with clinical stage,lymph node metastasis(P＞0.05).
Conclusion:1、CD10 protein expression was markedly reduced or completely absent in pulmonary carcinoma,tumor stromal cells.CD10 can serve as a valuable tumor marker for lung cancer diagnosis and differential diagnosis.There was correlation between loss of CD10 expression and most clinicopathologic parameters including age,pathological type, differentiation,clinical stage,lymph node metastasis.Diminished or even loss of CD10 expression may be important in the pulmonary carcinogenesis.2、CD13 protein expression was markedly increased in pulmonary carcinoma,tumor stromal cells.CD13 can serve as a valuable tumor marker for lung cancer diagnosis and differential diagnosis. There was correlation between loss of CD13 expression and most clinicopathologic parameters including pathological type,differentiation,clinical stage,lymph node metastasis.Raise of CD13 expression may be important in the pulmonary carcinogenesis. 3、NY-ESO-1 and MAGE-A1 are expressed only in pulmonary carcinoma and not in the adjacent tissues,lung benign tumor,normal lung tissues.The expression of NY-ESO-1 was related to pathological classification of lung cancer,clinical stage,pathological differentiation and lymph node metastasis.The expression of MAGE-A1 was also related to pathological classification of lung cancer and pathological differentiation,however, expression rate of MAGE-1 has no relationship with clinical stage,lymph node metastasis. 4、A combination of these four markers:CD10,CD13,NY-ESO-1 and MAGE-A1,is helpful in the differential diagnosis of pulmonary carcinoma.
引文
[1]. Kerr MA, Kenny AJ. The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem J, 1974,137(3):477-88.
[2]. Shousha, S, Gadir, F, Peston, D, et al. CD10 immunostaining of bile canaliculi in liver biopsies: change of staining pattern with the development of cirrhosis. Histopathology, 2004,45(4):335-342.
[3]. Cohen AJ, Bum PA, Franklin W, Magill-Solc C, Christa H,Barbara H, Gilman L, Folkvord J, Helm K, Miller YE. Neutral endopeptidase: Variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux. Cancer Res 1996;56:831-839.
[4]. Nahye Myong, M.D. Loss of CD10/NEP Expression in the Pulmonary Carcinogenesis Cancer Research and Treatment 2002;34 (1) : 17-22
[5]. Tokuhara T, Adachi M, Hashida H, Ishida H, Taki T, Higashiyama M, Kodama K, Tachibana S, Sasaki S, Miyake M.Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg 2001;49:489-496.
[6]. Cohen AJ, Gilman LB, Moore M, Franklin WA, Miller YE.Inactivation of neutral endopeptidase in lung cancer. Chest 1996;109(Suppl):125-135.
[7]. Dusser DJ, Djokic TD, Borson DB, Nadel JA. Cigarette smoke induces bronchoconstrictor hyperresponsiveness to substance Pand inactivates airway neutral endopeptidase in the guinea pig.Possible role of free radicals. J Clin Invest 1989;84:900-906.
[8]. Kim MK, Kim HK, Kim I, Han J, Huh SJ, Ahn YH, Kim DY, Shim YM. p53 expression in non-small cell lung cancer.Its relationship to the clinical prognostic factor and smoking history. J Korean Cancer Assoc 1999;31:1219-1226.
[9]. Nahye Myong, M.D. Loss of CD10/NEP Expression in the Pulmonary Carcinogenesis Cancer Research and Treatment 2002;34 (1) : 17-22
[10]. Cohen AJ, Bunn PA, Franklin W, Magill-Solc C, Christa H,Barbara H, Gilman L, Folkvord J, Helm K, Miller YE. Neutral endopeptidase: Variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux. Cancer Res 1996;56:831-839.
[11].Kehlen A, Langner J, Riemann D. Transforming growth factor-h increases the expression of aminopeptidase N/CD13 mRNA and protein in monocytes and monocytic cell lines. Adv ExpM ed Biol 2004;77: 49-56.
[12]. Ishii K, Usui S, Sugimura Y, et al. Aminop ep tidaseN regulated by zinc in human prostate participates in tumor cell invasion. Int J Cancer 2001;92:49-54.
[13]. Van Hembergen Y, Broxtennan UJ, Hanemaaijer R, et al. Soluble aminopeptidase N / CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clin Cancer Res, 2002, 8(12): 3747
[14]. Murakami H, Yokoyama A, Kondo K, Nakanishi S, Kohno N, Miyake M. Circulating Aminopeptidase N/CD13 Is an Independent Prognostic Factor in Patientswith Non-Small Cell Lung Cancer .Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8674-8679
[15].Ikeda N,Nakajima Y,Tokuhara T,et al.Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. ClinCancer Res, 2003, 9(4):1503-1508.
[16].Hashida H, Takabayashi A, Kanai M, et al. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer.Gastroenterology, 2002,122(2):376-386.
[17].Kido A, Krueger S, Haeckel C, Roessner A. Inhibitory effect of antisense aminopeptidase N (APN/CD13) cDNA transfection on the invasive potential of of osteosarcoma cells. Clin Exp Metastasis, 2003, 20(7): 585
[18].Moinfar F , Man YG, Arnould L , et al . Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma : implications for tumorigenesis. Cancer Res ,2000 ,60 : 2562-2566.
[19].Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000; 60:722-727.
[20].Hashida H,Takabayashi A, KanaiM, et al.Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer.Gastroenterology 2002; 122:376-386.
[21].Scanlan,MJ,Simp son AJ,Old LJ,et al.The cancer/testis genes:review,standardization,and commentary[J].Cancer Immun,2004,4(1):1.
[22].Chen YT,Scanlan MJ,Sahin U,et al.A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening[J].Proc Natl Acad Sci USA,1997,94(5):1914-1918.
[23].Jager E,Gnjatic S,Nagata Y,el al.A induction of primary NY-ES0-1immunity:CD8+T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1 cancers[J].Proc Natl Acad Sci USA,2000,97(22):12198-12203.
[24].Li-LiChen,Guillaume Stewart-Jones,Giovanna Bossi,et al.Structural and kinetic basis for heightened immunogenicity of T cell vaccines[J].J Exp Med,2005,201(8):1243
[25].Zhao Y,Zheng Z,Khong HT,et al.Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CIM+lymphocytes[J].J Immunother,2006,29(4):398.
[26].PurbhooMA,Sutton DH,Brewer JE,et al.Quantifying and imaging NY-ESO-1/LAGE-1 derived epitopes on tumor cells using high affinity T cell receptors[J].J Immunol,2006,176(12):7308.
[27].Jager E,Gnjatic S,Yasuhiro N,et al.Induction of primary NY-ESO-1 immunity:CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO 卜 1+cancers.PNAS.2000,97(22):12198-12203.
[28].Scanlan MJ,Gure AO,Jungbluth AA,ct aL Cancer/testis antigens:an expanding family of targets for can cer immunotherapy.Immunol Rev,2002,188:22-32.
[29].Sharma P,Gnjatic S,Jungbluth AA,ct al.Frequency of NY-ESO-1 and LAGE-1expression in bladder cancer an d evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder carlccK Cancer Immun,2003,3:19.
[30].Akcakanat A,Kanda T,Tanabe T,et.al.Heterogeneous expression of GAGE,NY-ESO-1,MAGE-A1 and SSX proteins in esophageal cancer:Implications for immunotherapy[J].IntJCancer,2006,118(1):123.
[31].Haier J,Owzcareck M,Guler U,et al.Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas[J].Anticancer Res,2006,26(3B): 2281.
[32].Gure AO,Wei,Old U,et al.The SSX gene family:characterization of complete genes[J].Int J Cancer,2002,101(5):448-453.
[33].Coral S,Sigalotti L,Altomonte M,ct al.5-aza-2'-deoxycytidine induced expression of functional can cer testis an tigens in human renal cell carcinoma:immunotherapeutic implications[J].Clin Cancer Res,2002,8(8):2690-2695.
[34].Schrump DS,FischetteMR,Nguyen DM,et al.Phase Ⅰ study of decitabine-mediated gene expression in patients with cancers involving the lungs,esophagus,or pleura[J].Clin Cancer Res,2006,12(19):5777-5785.
[35].Jang S J,Sofia J C,Wang L,et al.Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis[J].Cancer Res,2001,61(21):7959-7963.
[36].Sugita Y,Wada H,Fujita S,et al.NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors[J].Cancer Res,2004,64(6):2199-2204.
[37].Konishi J,Toyooka S,Aoe M,el al.The relationship between NY-ESO-1mRNA expression and clinicopatholo calfeatures in non-small cell lung cancer[J].Oncol Rep,2004,11(5):1063-1067.
[38].Scanlan MJ,Gure AOo Jungbluth AA,et al.Cancer/testis antigens:all expanding family of targets for cancer immunotherapy[J].Immunol Rev,2002,188(1):22-32.
[39].Kurashige T,Noguchi Y,Saika T,et al.Ny-ESO-1 expression and immunogenicity associated with transitional cel carcinoma:correlation with tumor grade[J].Cancer Res,2ool,61:4671-4674
[40].赵辉,沈晨阳,王丹蕾,张国良,王俊.肿瘤睾丸抗原(CTA)在肺癌中的表达[J].中国肺癌杂志,2002,(05)330-333
[41].Sugita Y,Wada H,Fujita S,et al.NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors[J].Cancer Res,2004,64(6):2199-2204.
[42].Luo G,Huan g S,Xie X,et al.Expresion of cancer-testis genes in humall hepatocellular carcinomas.Cancer Inlnlun.2002.2:11.68.
[43].Sahin U,Tureci O,Chen YT,et al.Expression ofmultiple cancer/testis(CT)antigens in breast cancer and melanoma:basis for polyvalent CT vaccine strategies[J].Int J Cancer, 1998, 78(3): 387-389.
[44]. Tajima K, Obata Y, Tamaki H, et al. Expression of cancer/testis(CT)antigens in lung cancer[J]. Lung Cancer, 2003, 42(1): 23-33.
[1]. Sumitomo M, Milowsky MI, Shen R, et al. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res, 2001,61(8):3294-3298.
[2]. Sumitomo M, Asano T,Asakuma J,et al. Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase. Clin Cancer Res, 2004,10(1):260-266.
[3]. Akira I, Ruoqian S, Daniel N, et al. Direct Binding of Neutral Endopeptidase 24.11 to Ezrin/Radixin/Moesin (ERM) Proteins Competes with the Interaction of CD44 with ERM Proteins. J. Biol. Chem, 2004,279(12):11898-11905.
[4]. Sumitomo M, Shen R, Nanus DM. Involvement of neutral endopeptidase in neoplastic progression. Biochim Biophys Acta, 2005,1751(1):52-59.
[5]. Goodman OB Jr, Febbraio M, Simantov R, et al. Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2. J Biol Chem, 2006,281 (44):33597-33605.
[6]. Yasojima K, Akiyama H, McGeer EG, et al. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci Lett, 2001,297(2):97-100.
[7]. Ogawa T, Kiryu-Seo S, Tanaka M, et al. Altered expression of neprilysin family members in the pituitary gland of sleep-disturbed rats, an animal model of severe fatigue. J Neurochem, 2005,95(4): 1156-1166.
[8]. Uematsu F, Takahashi M, Yoshida M, et al. Methylation of neutral endopeptidase 24.11 promoter in rat hepatocellular carcinoma. Cancer Sci, 2006,97(7):611-617.
[9]. Pardossi-Piquard R, Dunys J, Yu G, et al. Neprilysin activity and expression are controlled by nicastrin. J Neurochem, 2006,97(4): 1052-1056.
[10]. Saito T, Iwata N, Tsubuki S et al. Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation. Nat. Med, 2005,11(4): 434-439..
[11]. Ayoub S, Melzig MF. Induction of neutral endopeptidase (NEP) activity of SK-N-SH cells by natural compounds from green tea. J Pharm Pharmacol,2006,58(4): 495-501.
[12]. Tomoda C, Kushima R, Takeuti E, et al. CD 10 expression is useful in the diagnosis of follicular carcinoma and follicular variant of papillary thyroid carcinoma. Thyroid, 2003,13(3):291-295.
[13]. Yasuda Masanori. Itoh Johbu. Satoh Yoshihiro.et al.Availability of CD10 as a Histopathological Diagnostic Marker. Acta Histochem Cytochem, 2005,38(1):17-24.
[14]. Yao T, Tustsumi S, Akaiwa Y, et al. Phenotypic expression of colorectal adenocarcinoma with reference to tumor development an biological behavior. Jpn J Cancer Res, 2001,92(12):755-761.
[15]. Langner C, Ratschek M, Rehak P, et al. CD10 is a diagnostic and prognostic marker in renal malignancies. Histopathology, 2004,45(5):460-467.
[16]. 16 Osman I, Yee H, Taneja SS, et al. Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res, 2004,10(12):4096-4100.
[17]. Freedland SJ, Seligson DB, Liu AY, et al. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate, 2003,55(1):71-80.
[18]. Bahrami S, Malone JC, Lear S, et al. CD10 expression in cutaneous adnexal neoplasms and a potential role for differentiating cutaneous metastatic renal cell carcinoma. Arch Pathol Lab Med, 2006,130(9):1315-1319.
